NPCE
What one share of Neuropace holds
Surgical and Medical Instruments and Apparatus
We are a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Our novel and differentiated RNS System is the first and only commercially available, brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source.
Neuropace’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.19 |
|---|---|
| Profit | −$0.57 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.35 |
| Dividends | $0.00 |
| Cash and investments | $0.37 |
| Debt | $1.72 |
| Book value | $0.35 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $201.59 | −$117.85 | $0.30 | −$106.19 | — | −$470.66 |
| 2021 | $2.72 | −$2.17 | $0.02 | −$1.50 | — | $3.01 |
| 2022 | $1.85 | −$1.91 | $0.02 | −$1.52 | — | $1.39 |
| 2023 | $2.53 | −$1.27 | $0.01 | −$0.77 | $0.00 | $0.74 |
| 2024 | $2.74 | −$0.93 | $0.01 | −$0.63 | $0.00 | $0.27 |
| 2025 | $3.06 | −$0.66 | $0.01 | −$0.35 | $0.00 | $0.57 |